Page last updated: 2024-08-25

zoledronic acid and Hypocalcemia

zoledronic acid has been researched along with Hypocalcemia in 52 studies

Research

Studies (52)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	23 (44.23)	29.6817
2010's	24 (46.15)	24.3611
2020's	5 (9.62)	2.80

Authors

Authors	Studies
Abe, S; Kamatani, T; Kashii, M; Koizumi, K; Kuriyama, K; Mizuno, N; Yamamoto, K; Yoshida, A; Yoshikawa, H	1
Arnaud, M; Bioteau, C; Blain, H; Boudissa, M; Drevet, S; Gavazzi, G; Jalbert, R; Parent, T; Tonetti, J	1
Bharucha, T; Case, SJ; Davies, JH; Moon, RJ	1
Elazzazy, S; Hamad, A; Nasser, SM; Sahal, A	1
Sözel, H; Yilmaz, F	1
Billias, C; Langer, M; Schorr, R; Ursu, S	1
Bastida, C; Chaguaceda, C; Creus-Baró, N; Manzaneque, A; Mensa, M	1
Hirasawa, N; Imatoh, T; Sai, K; Saito, Y; Segawa, K; Takeyama, M	1
Conca, P; Di Minno, G; Matani, B; Rendina, D; Tufano, A	1
Hiramatsu, T; Hori, K; Imatoh, T; Kataoka, Y; Kawakami, J; Kimura, M; Nakashima, N; Ohe, K; Sai, K; Saito, Y; Segawa, K; Takeyama, M; Yamashita, T; Yokoi, H	1
Coleman, RE; Fizazi, K; Galsky, MD; Gartrell, BA; Miller, K; Saad, F; Sternberg, CN	1
Cure, E; Cure, MC; Yuce, S	1
Abe, M; Kawazoe, K; Kujime, T; Minakuchi, K; Okada, N; Shinohara, Y; Teraoka, K	1
Body, JJ	1
Choueiri, TK; Heng, DY; Lin, X; McKay, RR; Perkins, JJ; Simantov, R	1
Blum, C; Borm, K; Kreutle, V; Meier, C; Müller, B; Past, M; Schütz, P	1
Jaiswal, S; Noriega Aldave, AP	1
Body, JJ; Bone, HG; Bracco, OL; Braun, A; Damião, R; de Boer, RH; Fizazi, K; Henry, DH; Ibrahim, T; Kostenuik, PJ; Lipton, A; Saad, F; Shaywitz, AJ; Shore, N; Stopeck, A; Takano, T; Van Poznak, C; Wang, H	1
Cheung, MS	1
George, S; Hummel, K; Kaplan, P; Levine, MA; Monk, HM; Weber, DR	1
Epperla, N; Pathak, R	1
Chakrabarti, SS; Gambhir, IS; Kaur, U	1
Kannan, S; Mahadevan, S; Sathya, A; Sriram, U	1
Azizkhan, RG; Heubi, JE; Lucky, AW; Perman, MJ	1
Ariyama, H; Baba, E; Esaki, T; Fujimoto, C; Hiranuma, S; Murakawa, M; Syoji, T; Tsukasa, K	1
Berlusconi, M; Biancofiore, G; Giordano, L; Gullo, G; Masci, G; Navarria, P; Santoro, A; Scorsetti, M; Tancioni, F; Zuradelli, M	1
Hanamura, M; Iwamoto, T; Okuda, M; Soga, N; Sugimura, Y	1
Anastasilakis, AD; Arsos, G; Efstathiadou, Z; Kita, M; Litsas, I; Moralidis, E; Papatheodorou, A; Polyzos, SA; Terpos, E	1
Hamdy, RC	1
Ho, JW; Sundar, S	1
Beuzeboc, P; Bilynskyy, B; Braun, A; Brown, JE; Charu, V; Clemens, M; Fizazi, K; Henry, DH; Jun, S; Ke, C; Lipton, A; Maroto, P; Rader, M; Richardson, GE; Saad, F; Siena, S; Stopeck, AT; Viniegra, M; Yardley, DA	1
Carducci, MA; Paller, CJ; Philips, GK	1
Correa, PH; Ferraz-de-Souza, B; Martin, RM	1
Dolan, G; Jones, SG; Lengyel, K; Myers, B	1
Fraser, WD; Mishra, V; Peter, R	1
Choudhury, AM; Tanvetyanon, T	1
Breen, TL; Shane, E	1
Breay, S	1
Tanvetyanon, T	1
Khaira, NS; Sekhon, JS; Singh, D	1
Brahmbhatt, V; Patel, K; Ramu, V	1
Beilin, J; Ingram, KB; Nguyen, HV	1
Cull, G; Henley, D; Kaye, J; Walsh, J	1
Angus, PW; Byth, K; Crawford, BA; Handelsman, DJ; Kam, C; McCaughan, GW; Pavlovic, J	1
Bodmer, M; Kummer, O; Ramazzina, C; Rätz Bravo, AE; Zysset Aschmann, Y	1
Briody, J; Cowell, CT; Högler, W; Hong, J; Little, DG; McQuade, M; Munns, CF; Rajab, MH	1
de Nijs, RN; Westgeest, AA	1
Kaptoge, S; Poole, KE; Reeve, J	1
Chahine, GY; Farhat, FS; Ghosn, MG; Kattan, JG; Moukadem, WT; Nasr, FL; Yazbeck, NJ; Younes, FC	1
Arlen, PM; Dahut, WL; Gulley, JL; Wu, S	1
Alaña, M; Cruz, JJ; Fonseca, E; Leno, R; López, R; Navarro, M; Ocaña, A; Sánchez, F	1
Baumann, MA; Chennuru, S; Koduri, J	1

Reviews

8 review(s) available for zoledronic acid and Hypocalcemia

Article	Year
Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer. European urology, 2014, Volume: 65, Issue:2 Topics: Androgen Antagonists; Antibodies, Monoclonal, Humanized; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Fractures, Bone; Humans; Hypocalcemia; Imidazoles; Male; Molecular Targeted Therapy; Osteoclasts; Patient Selection; Prostatic Neoplasms; RANK Ligand; Risk Factors; Treatment Outcome; Zoledronic Acid	2014
[Inhibition of RANK ligand to treat bone metastases]. Bulletin du cancer, 2013, Volume: 100, Issue:11 Topics: Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Female; Humans; Hypocalcemia; Imidazoles; Male; Multiple Myeloma; Prostatic Neoplasms; RANK Ligand; Zoledronic Acid	2013
Bisphosphonate induced hypocalcaemia - report of six cases and review of the literature. Swiss medical weekly, 2014, Volume: 144 Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Calcitriol; Calcium; Diphosphonates; Female; Humans; Hypocalcemia; Imidazoles; Male; Middle Aged; Vitamins; Zoledronic Acid	2014
Drugs Used in Paediatric Bone and Calcium Disorders. Endocrine development, 2015, Volume: 28 Topics: Acetazolamide; Bone and Bones; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcitonin; Calcitriol; Calcium; Child; Denosumab; Diphosphonates; Diuretics; Glucocorticoids; Humans; Hypercalcemia; Hyperphosphatemia; Hypocalcemia; Hypophosphatemia; Imidazoles; Osteoporosis; Parathyroid Hormone; Phosphates; Risedronic Acid; Sodium Potassium Chloride Symporter Inhibitors; Vitamin D; Zoledronic Acid	2015
Zoledronic acid: clinical utility and patient considerations in osteoporosis and low bone mass. Drug design, development and therapy, 2010, Nov-18, Volume: 4 Topics: Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Female; Humans; Hypocalcemia; Imidazoles; Kidney; Male; Osteoporosis; Patient Compliance; Zoledronic Acid	2010
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. European journal of cancer (Oxford, England : 1990), 2012, Volume: 48, Issue:16 Topics: Antibodies, Monoclonal, Humanized; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Clinical Trials, Phase III as Topic; Denosumab; Diphosphonates; Disease Progression; Female; Humans; Hypocalcemia; Imidazoles; Male; Middle Aged; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Survival Analysis; Time Factors; Treatment Outcome; Zoledronic Acid	2012
Management of bone metastases in refractory prostate cancer--role of denosumab. Clinical interventions in aging, 2012, Volume: 7 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Neoplasms; Denosumab; Diphosphonates; Disease-Free Survival; Humans; Hypocalcemia; Imidazoles; Male; Orchiectomy; Osteonecrosis; Prostatic Neoplasms; Randomized Controlled Trials as Topic; RANK Ligand; Zoledronic Acid	2012
[Zoledronate-associated end stage renal failure and hypocalcaemia]. Praxis, 2007, Apr-25, Volume: 96, Issue:17 Topics: Acute Kidney Injury; Adverse Drug Reaction Reporting Systems; Age Factors; Aged; Aged, 80 and over; Biopsy; Bone Density Conservation Agents; Calcium; Creatinine; Diphosphonates; Disease Progression; Female; Follow-Up Studies; Humans; Hypocalcemia; Imidazoles; Kidney Failure, Chronic; Kidney Tubules; Middle Aged; Multiple Myeloma; Pamidronate; Renal Dialysis; Risk Factors; Switzerland; Time Factors; Vitamin D; Zoledronic Acid	2007

Trials

4 trial(s) available for zoledronic acid and Hypocalcemia

Article	Year
Identification of the risk factors associated with hypocalcemia induced by denosumab. Biological & pharmaceutical bulletin, 2013, Volume: 36, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Resorption; Calcium; Creatinine; Denosumab; Diphosphonates; Female; Humans; Hypocalcemia; Imidazoles; Logistic Models; Male; Middle Aged; Neoplasms; Odds Ratio; Osteoclasts; RANK Ligand; Retrospective Studies; Risk Factors; ROC Curve; Zoledronic Acid	2013
Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial. Annals of internal medicine, 2006, Feb-21, Volume: 144, Issue:4 Topics: Bone Density; Bone Density Conservation Agents; Chronic Disease; Diphosphonates; Double-Blind Method; Follow-Up Studies; Humans; Hydroxycholecalciferols; Hyperparathyroidism, Secondary; Hypocalcemia; Imidazoles; Infusions, Intravenous; Liver Failure; Liver Transplantation; Osteoporosis; Parathyroid Hormone; Zoledronic Acid	2006
Acute phase response and mineral status following low dose intravenous zoledronic acid in children. Bone, 2007, Volume: 41, Issue:3 Topics: Acute-Phase Reaction; Adolescent; Bone Density Conservation Agents; Bone Diseases; C-Reactive Protein; Calcium; Child; Child, Preschool; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Hypocalcemia; Imidazoles; Infusions, Intravenous; Male; Parathyroid Hormone; Phosphates; Zoledronic Acid	2007
Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC). Investigational new drugs, 2008, Volume: 26, Issue:1 Topics: Administration, Oral; Aged; Aged, 80 and over; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Diphosphonates; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Estramustine; Fatigue; Humans; Hypocalcemia; Imidazoles; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Thrombocytopenia; Time Factors; Treatment Outcome; Zoledronic Acid	2008

Other Studies

40 other study(ies) available for zoledronic acid and Hypocalcemia

Article	Year
Tolerability of the first infusion of once-yearly zoledronic acid within one to two weeks after hip fracture surgery. Bone, 2022, Volume: 155 Topics: Aged, 80 and over; Antipyretics; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Hip Fractures; Humans; Hypocalcemia; Imidazoles; Male; Osteoporosis; Vitamin D; Zoledronic Acid	2022
Zoledronic Acid Contraindications Prevalence among Hip-Fractured Patients Aged 75 Years or Over Hospitalized in an Orthogeriatric Unit. Gerontology, 2022, Volume: 68, Issue:11 Topics: Aged; Aged, 80 and over; Creatinine; Female; Hip Fractures; Hospitalization; Humans; Hypocalcemia; Prevalence; Retrospective Studies; Zoledronic Acid	2022
Intracardiac thrombosis following intravenous zoledronate treatment in a child with steroid-induced osteoporosis. Journal of pediatric endocrinology & metabolism : JPEM, 2023, Mar-28, Volume: 36, Issue:3 Topics: Bone Density Conservation Agents; Child; Diphosphonates; Humans; Hypocalcemia; Imidazoles; Male; Osteoporosis; Steroids; Thrombosis; Zoledronic Acid	2023
Effect of denosumab versus zoledronic acid on calcium levels in cancer patients with bone metastasis: A retrospective cohort study. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2019, Volume: 25, Issue:8 Topics: Bone Density Conservation Agents; Bone Neoplasms; Calcium; Cohort Studies; Denosumab; Female; Humans; Hypercalcemia; Hypocalcemia; Incidence; Male; Middle Aged; Retrospective Studies; Zoledronic Acid	2019
Symptomatic hypocalcemia following a single dose of zoledronic acid in a patient with bone metastases secondary to breast cancer. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2021, Volume: 27, Issue:2 Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Humans; Hypocalcemia; Hypophosphatemia; Magnetic Resonance Imaging; Middle Aged; Positron-Emission Tomography; Vitamin D Deficiency; Zoledronic Acid	2021
Safety and efficacy of bone-modifying agents among multiple myeloma patients: A retrospective cohort study. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2022, Volume: 28, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Humans; Hypocalcemia; Middle Aged; Multiple Myeloma; Osteonecrosis; Retrospective Studies; Young Adult; Zoledronic Acid	2022
Use and safety of denosumab in cancer patients. International journal of clinical pharmacy, 2017, Volume: 39, Issue:3 Topics: Aged; Aged, 80 and over; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Calcium; Denosumab; Diphosphonates; Female; Follow-Up Studies; Guideline Adherence; Humans; Hypocalcemia; Imidazoles; Male; Middle Aged; Neoplasms; Practice Guidelines as Topic; Retrospective Studies; Tertiary Care Centers; Vitamin D; Zoledronic Acid	2017
Influence of Japanese Regulatory Action on Denosumab-Related Hypocalcemia Using Japanese Adverse Drug Event Report Database. Biological & pharmaceutical bulletin, 2017, Volume: 40, Issue:9 Topics: Adverse Drug Reaction Reporting Systems; Algorithms; Asian People; Bone Density Conservation Agents; Databases, Factual; Denosumab; Diphosphonates; Humans; Hypocalcemia; Imidazoles; Japan; Jaw Diseases; Logistic Models; Odds Ratio; Osteonecrosis; Zoledronic Acid	2017
Hypocalcemia and hypophosphatemia after treatment with zoledronic acid in a patient with AL amyloidosis. Internal and emergency medicine, 2019, Volume: 14, Issue:3 Topics: Administration, Intravenous; Bone Density Conservation Agents; Fatigue; Humans; Hypocalcemia; Hypophosphatemia; Immunoglobulin Light-chain Amyloidosis; Male; Middle Aged; Zoledronic Acid	2019
Evaluating the impact of regulatory action on denosumab-induced hypocalcaemia in Japan. Journal of clinical pharmacy and therapeutics, 2019, Volume: 44, Issue:5 Topics: Aged; Bone Density Conservation Agents; Calcium; Databases, Factual; Denosumab; Female; Humans; Hypocalcemia; Japan; Male; Risk Factors; Vitamin D; Zoledronic Acid	2019
Severe hypocalcemia associated with zoledronic acid treatment in a patient with a risk of fracture due to drug-induced osteopenia. Minerva endocrinologica, 2013, Volume: 38, Issue:2 Topics: Absorptiometry, Photon; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Female; Fractures, Bone; Humans; Hypocalcemia; Imidazoles; Lupus Erythematosus, Systemic; Middle Aged; Risk; Zoledronic Acid	2013
Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma. European urology, 2014, Volume: 66, Issue:3 Topics: Aged; Antineoplastic Agents; Axitinib; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Disease-Free Survival; Female; Humans; Hypocalcemia; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Pamidronate; Phenylurea Compounds; Prognosis; Pyrroles; Renal Insufficiency; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Zoledronic Acid	2014
Severe resistant hypocalcemia in multiple myeloma after zoledronic acid administration: a case report. Journal of medical case reports, 2014, Oct-23, Volume: 8 Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Hypocalcemia; Imidazoles; Multiple Myeloma; Tomography, X-Ray Computed; Vitamin D Deficiency; Zoledronic Acid	2014
Hypocalcaemia in patients with metastatic bone disease treated with denosumab. European journal of cancer (Oxford, England : 1990), 2015, Volume: 51, Issue:13 Topics: Antineoplastic Agents; Biomarkers; Bone Density Conservation Agents; Bone Neoplasms; Calcium; Clinical Trials, Phase III as Topic; Denosumab; Diphosphonates; Humans; Hypocalcemia; Imidazoles; Incidence; Retrospective Studies; Risk Assessment; Risk Factors; Severity of Illness Index; Time Factors; Treatment Outcome; Vitamin D Deficiency; Zoledronic Acid	2015
Short-Term Safety of Zoledronic Acid in Young Patients With Bone Disorders: An Extensive Institutional Experience. The Journal of clinical endocrinology and metabolism, 2015, Volume: 100, Issue:11 Topics: Acute-Phase Reaction; Adolescent; Alkaline Phosphatase; Bone Density Conservation Agents; Bone Diseases; Calcitriol; Calcium; Child; Child, Preschool; Diphosphonates; Female; Humans; Hypercalcemia; Hypocalcemia; Hypophosphatemia; Imidazoles; Infant; Male; Osteogenesis Imperfecta; Osteoporosis; Prospective Studies; Retrospective Studies; Risk Factors; Young Adult; Zoledronic Acid	2015
Hypocalcemia Secondary to Zoledronate Therapy in a Patient With Low Vitamin D Level. WMJ : official publication of the State Medical Society of Wisconsin, 2015, Volume: 114, Issue:4 Topics: Bone Density Conservation Agents; Calcium; Diphosphonates; Humans; Hypocalcemia; Hypoparathyroidism; Imidazoles; Lung Neoplasms; Male; Middle Aged; Risk Factors; Small Cell Lung Carcinoma; Vitamin D Deficiency; Zoledronic Acid	2015
Zoledronate Induced Hypocalcemia and Hypophosphatemia in Osteoporosis: A Cause of Concern. Current drug safety, 2016, Volume: 11, Issue:3 Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Humans; Hypocalcemia; Hypophosphatemia; Imidazoles; Male; Osteoporosis; Zoledronic Acid	2016
A tale of three diseases of the bone. Singapore medical journal, 2008, Volume: 49, Issue:10 Topics: Absorptiometry, Photon; Aged; Bone and Bones; Bone Density; Calcium Carbonate; Cholecalciferol; Diphosphonates; Female; Humans; Hypocalcemia; Imidazoles; Lumbar Vertebrae; Osteitis Deformans; Osteomalacia; Vitamin D Deficiency; Zoledronic Acid	2008
Severe symptomatic hypocalcemia in a patient with RDEB treated with intravenous zoledronic acid. Archives of dermatology, 2009, Volume: 145, Issue:1 Topics: Adolescent; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Epidermolysis Bullosa Dystrophica; Humans; Hypocalcemia; Imidazoles; Male; Zoledronic Acid	2009
[A case of bone marrow carcinosis from gastric cancer that presented hypocalcemia caused by zoledronic acid during the treatment of methotrexate/5-fluorouracil sequential therapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow; Calcinosis; Diphosphonates; Fatal Outcome; Fluorouracil; Gastroscopy; Humans; Hypocalcemia; Imidazoles; Magnetic Resonance Imaging; Male; Methotrexate; Middle Aged; Stomach Neoplasms; Tomography, X-Ray Computed; Zoledronic Acid	2009
High incidence of hypocalcemia and serum creatinine increase in patients with bone metastases treated with zoledronic acid. The oncologist, 2009, Volume: 14, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Calcium; Creatinine; Diphosphonates; Female; Humans; Hypocalcemia; Imidazoles; Incidence; Kidney; Male; Middle Aged; Serum Albumin; Zoledronic Acid	2009
Risk factors contributing to the development of hypocalcemia after zoledronic acid administration in patients with bone metastases of solid tumor. Biological & pharmaceutical bulletin, 2010, Volume: 33, Issue:4 Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Calcium; Diphosphonates; Female; Humans; Hypocalcemia; Imidazoles; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Prostatic Neoplasms; Retrospective Studies; Risk Factors; Zoledronic Acid	2010
Profound hypocalcemia following effective response to zoledronic acid treatment in a patient with juvenile Paget's disease. Journal of bone and mineral metabolism, 2010, Volume: 28, Issue:6 Topics: Adult; Bone and Bones; Bone Density Conservation Agents; Diphosphonates; Drug Monitoring; Female; Humans; Hyperparathyroidism, Secondary; Hypocalcemia; Imidazoles; Osteitis Deformans; Radiography; Zoledronic Acid	2010
Prolonged hypocalcemia after zoledronic acid in a patient with metastatic prostate carcinoma: did zoledronic acid trigger osteoblastic activity and avid calcium uptake? Clinical genitourinary cancer, 2012, Volume: 10, Issue:1 Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Calcium; Diphosphonates; Humans; Hypocalcemia; Imidazoles; Male; Osteoblasts; Prostatic Neoplasms; Treatment Outcome; Zoledronic Acid	2012
Symptomatic intracranial hypertension and prolonged hypocalcemia following treatment of Paget's disease of the skull with zoledronic acid. Journal of bone and mineral metabolism, 2013, Volume: 31, Issue:3 Topics: Diphosphonates; Female; Humans; Hypocalcemia; Imidazoles; Intracranial Hypertension; Middle Aged; Osteitis Deformans; Radionuclide Imaging; Skull; Tomography, X-Ray Computed; Zoledronic Acid	2013
Severe increase in creatinine with hypocalcaemia in thalidomide-treated myeloma patients receiving zoledronic acid infusions. British journal of haematology, 2002, Volume: 119, Issue:2 Topics: Aged; Creatinine; Diphosphonates; Female; Humans; Hypocalcemia; Imidazoles; Immunosuppressive Agents; Male; Multiple Myeloma; Thalidomide; Zoledronic Acid	2002
Severe hypocalcaemia after being given intravenous bisphosphonate. BMJ (Clinical research ed.), 2004, Feb-07, Volume: 328, Issue:7435 Topics: Bone Resorption; Diphosphonates; Female; Humans; Hypercalcemia; Hypocalcemia; Imidazoles; Male; Middle Aged; Neoplasms; Zoledronic Acid	2004
Hypocalcemia and azotemia associated with zoledronic acid and interferon alfa. The Annals of pharmacotherapy, 2004, Volume: 38, Issue:3 Topics: Adult; Antineoplastic Agents; Carcinoid Tumor; Diphosphonates; Humans; Hypocalcemia; Imidazoles; Interferon-alpha; Male; Uremia; Zoledronic Acid	2004
Prolonged hypocalcemia after treatment with zoledronic acid in a patient with prostate cancer and vitamin D deficiency. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Apr-15, Volume: 22, Issue:8 Topics: Bone Neoplasms; Diphosphonates; Humans; Hypocalcemia; Imidazoles; Male; Prostatic Neoplasms; Vitamin D Deficiency; Zoledronic Acid	2004
Hypocalcaemia after intravenous bisphosphonate: read the product information first. BMJ (Clinical research ed.), 2004, Jun-12, Volume: 328, Issue:7453 Topics: Diphosphonates; Drug Labeling; Humans; Hypercalcemia; Hypocalcemia; Imidazoles; Infusions, Intravenous; Zoledronic Acid	2004
Is hypocalcemia during therapy with zoledronic acid or other bisphosphonates beneficial to cancer patients? Medical hypotheses, 2004, Volume: 63, Issue:4 Topics: Angiogenesis Inhibitors; Calcium; Diphosphonates; Humans; Hypocalcemia; Imidazoles; Models, Biological; Neoplasms; Neovascularization, Pathologic; Treatment Outcome; Zoledronic Acid	2004
Symptomatic hypocalcaemia after treatment with zoledronic acid in a patient with multiple myeloma. Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:12 Topics: Calcium; Diphosphonates; Female; Humans; Hypocalcemia; Imidazoles; Middle Aged; Multiple Myeloma; Zoledronic Acid	2004
Zoledronic acid-induced severe hypocalcaemia in a prostate cancer patient with extensive osteoblastic bone metastases. Tennessee medicine : journal of the Tennessee Medical Association, 2005, Volume: 98, Issue:2 Topics: Adenocarcinoma; Aged; Bone Neoplasms; Bone Resorption; Diphosphonates; Humans; Hypocalcemia; Imidazoles; Male; Pain; Prostatic Neoplasms; Zoledronic Acid	2005
Profound hypocalcaemia after zoledronic acid treatment. The Medical journal of Australia, 2005, May-02, Volume: 182, Issue:9 Topics: Aged; Aged, 80 and over; Diphosphonates; Female; Humans; Hypocalcemia; Imidazoles; Multiple Myeloma; Zoledronic Acid	2005
Symptomatic hypocalcaemia and renal impairment associated with bisphosphonate treatment in patients with multiple myeloma. Internal medicine journal, 2005, Volume: 35, Issue:12 Topics: Acute Kidney Injury; Aged; Bone Density Conservation Agents; Calcitriol; Calcium Carbonate; Diphosphonates; Fatal Outcome; Female; Humans; Hypocalcemia; Imidazoles; Injections, Intravenous; Magnesium Deficiency; Male; Middle Aged; Multiple Myeloma; Pamidronate; Zoledronic Acid	2005
Yearly zoledronic acid in postmenopausal osteoporosis. The New England journal of medicine, 2007, Aug-16, Volume: 357, Issue:7 Topics: Atrial Fibrillation; Bone Density Conservation Agents; Calcium; Diphosphonates; Drug Administration Schedule; Female; Fractures, Bone; Humans; Hypocalcemia; Imidazoles; Osteoporosis, Postmenopausal; Parathyroid Hormone; Zoledronic Acid	2007
Yearly zoledronic acid in postmenopausal osteoporosis. The New England journal of medicine, 2007, Aug-16, Volume: 357, Issue:7 Topics: Atrial Fibrillation; Bone Density Conservation Agents; Calcium; Diphosphonates; Female; Fractures, Bone; Humans; Hypocalcemia; Imidazoles; Osteoporosis, Postmenopausal; Parathyroid Hormone; Zoledronic Acid	2007
Persistent hypocalcemia induced by zoledronic acid in a patient with androgen-independent prostate cancer and extensive bone metastases. Clinical genitourinary cancer, 2007, Volume: 5, Issue:6 Topics: Adenocarcinoma; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Diphosphonates; Humans; Hypocalcemia; Imidazoles; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Zoledronic Acid	2007
Tonic-clonic seizure as the presentation symptom of severe hypocalcemia secondary to zoledronic acid administration. Journal of palliative medicine, 2007, Volume: 10, Issue:6 Topics: Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Epilepsy, Tonic-Clonic; Humans; Hypocalcemia; Imidazoles; Male; Severity of Illness Index; Spain; Zoledronic Acid	2007
Risk factors for symptomatic hypocalcaemia complicating treatment with zoledronic acid. Internal medicine journal, 2008, Volume: 38, Issue:8 Topics: Diphosphonates; Hospitals, Teaching; Humans; Hypocalcemia; Imidazoles; Incidence; Male; Retrospective Studies; Treatment Outcome; Zoledronic Acid	2008